Galmed Pharmaceuticals Ltd Asset Resilience Ratio

Latest as of June 2026: 45.65%

Galmed Pharmaceuticals Ltd asset resilience ratio. Galmed Pharmaceuticals Ltd (GLMD) has an Asset Resilience Ratio of 45.65% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Galmed Pharmaceuticals Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$8.35 Million

Cash + Short-term Investments

Total Assets

$18.28 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio of Galmed Pharmaceuticals Ltd (2014–2025)

Asset resilience ratio of Galmed Pharmaceuticals Ltd from 2014 to 2025. This chart shows how Galmed Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Read debt load of Galmed Pharmaceuticals Ltd for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Galmed Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GLMD total asset value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$8.35 Million	45.65%
Total Liquid Assets	$8.35 Million	45.65%

Asset Resilience Insights

Very High Liquidity: Galmed Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 45.65% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Galmed Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Galmed Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Hyloris Developmentsen Sa BR:HYL	Biotechnology	1.36%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Oruka Therapeutics, Inc. NASDAQ:ORKA	Biotechnology	53.11%
Gempharmatech Co. Ltd. A SHG:688046	Biotechnology	23.95%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	74.48%
Inventiva S.A PA:IVA	Biotechnology	52.73%
Sunmax Biotechnology Co Ltd TWO:4728	Biotechnology	10.53%
Guangdong VTR Bio-Tech Co Ltd SHE:300381	Biotechnology	4.98%

Galmed Pharmaceuticals Ltd Asset Resilience Ratio by Year (2014–2025)

Galmed Pharmaceuticals Ltd asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Galmed Pharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	76.08%	$14.17 Million	$18.63 Million	+18.35pp
2024-12-31	57.72%	$10.68 Million	$18.50 Million	-1.09pp
2023-12-31	58.82%	$9.78 Million	$16.63 Million	-12.25pp
2022-12-31	71.06%	$11.77 Million	$16.56 Million	-16.17pp
2021-12-31	87.23%	$31.93 Million	$36.60 Million	+3.35pp
2020-12-31	83.88%	$43.94 Million	$52.38 Million	+6.67pp
2019-12-31	77.21%	$59.56 Million	$77.14 Million	+4.33pp
2018-12-31	72.88%	$66.03 Million	$90.60 Million	+42.46pp
2017-12-31	30.42%	$5.98 Million	$19.64 Million	-44.66pp
2016-12-31	75.08%	$12.35 Million	$16.45 Million	-2.59pp
2015-12-31	77.67%	$18.84 Million	$24.26 Million	+52.61pp
2014-12-31	25.06%	$8.25 Million	$32.92 Million	--

pp = percentage points

About Galmed Pharmaceuticals Ltd

NASDAQ:GLMD USA Biotechnology

Market Cap

$4.10 Million

Market Cap Rank

#28901 Global

#5933 in USA

Share Price

$3.84

Change (1 day)

-6.11%

52-Week Range

$0.47 - $4.77

All Time High

$3232.80